<DOC>
	<DOCNO>NCT00416650</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study well erlotinib work treat patient advance non-small cell lung cancer .</brief_summary>
	<brief_title>Erlotinib Treating Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine major objective response rate ( partial response complete response ) patient advance bronchoalveolar cell non-small cell lung cancer treat erlotinib hydrochloride . Secondary - Assess quality life patient treat regimen . - Determine duration response time disease progression patient treat regimen . - Determine median survival patient treat regimen . OUTLINE : This open-label , nonrandomized , multicenter study . Patients receive oral erlotinib hydrochloride daily absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm bronchoalveolar cell ( variant ) nonsmall cell lung cancer ( NSCLC ) Stage IIIB ( malignant pleural pericardial effusion ) disease Stage IV disease Recurrent and/or medically inoperable disease Measurable evaluable indicator lesions No uncontrolled CNS metastasis ( i.e. , know CNS lesion radiographically unstable , symptomatic , and/or require escalate dos corticosteroid ) PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 01 OR Karnofsky PS 80100 % Life expectancy ≥ 8 week WBC ≥ 3,000/mm³ Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.0 mg/dL AST ≤ 2 time upper limit normal Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 55 mL/min Not pregnant nursing Fertile patient must use effective contraception No significant medical history unstable medical condition , include follow : Unstable systemic disease Congestive heart failure Recent myocardial infarction Unstable angina Active infection Uncontrolled hypertension No active malignancy within past 5 year except adequately treat carcinoma cervix basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 3 week since prior radiation therapy major bone marrowcontaining area At least 3 week since prior chemotherapy No 1 prior chemotherapy regimen NSCLC No prior systemic cytotoxic chemotherapy malignant diseases No prior erlotinib hydrochloride agent target HER family ( e.g. , cetuximab , trastuzumab [ Herceptin® ] , gefitinib ) No concurrent radiotherapy chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>